Nothing Special   »   [go: up one dir, main page]

Cunningham et al., 1988 - Google Patents

The pharmacokinetics of high dose cyclophosphamide and high dose etoposide

Cunningham et al., 1988

Document ID
7183757846592204553
Author
Cunningham D
Cummings J
Blackie R
McTaggart L
Banham S
Kaye S
Soukop M
Publication year
Publication venue
Medical oncology and tumor pharmacotherapy

External Links

Snippet

We have studied the pharmacokinetics of single agent high dose cyclophosphamide (HDC)(160–240 mg kg− 1) given as repeated intravenous (iv) infusions to six patients with small cell lung cancer (SCLC), and HDC (180 mg kg− 1) combined with ctoposide (750 …
Continue reading at link.springer.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR

Similar Documents

Publication Publication Date Title
Anderson et al. A study of the distribution of methotrexate in human tissues and tumors
Mukherjee et al. Studies on fluorinated pyrimidines: XVI. Metabolism of 5-fluorouracil-2-C14 and 5-fluoro-2′-deoxyuridine-2-C14 in cancer patients
Rustum et al. Correlation between leukemic cell retention of 1-β-D-arabinofuranosylcytosine 5′-triphosphate and response to therapy
Budman et al. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine.
Ginos et al. [13N] cisplatin PET to assess pharmacokinetics of intra-arterial versus intravenous chemotherapy for malignant brain tumors
Tirelli et al. Etoposide (VP-16-213) in malignant brain tumors: a phase II study.
Van Prooijen et al. The use of intermediate dose cytosine arabinoside (ID Ara‐C) in the treatment of acute non‐lymphocytic leukaemia in relapse
LePage et al. Pharmacology of 6-thioguanine in man
AU695696B2 (en) Pharmaceutical composition for treating osteoporosis
LePage et al. Studies of 9-β-D-arabinofuranosyladenine in man
Speth et al. Plasma and cellular adriamycin concentrations in patients with myeloma treated with ninety‐six‐hour continuous infusion
O'REILLY et al. Racemic warfarin and trimethoprim-sulfamethoxazole interaction in humans
US20190192602A1 (en) Improved Therapeutic Index of Anti-Immune Checkpoint Inhibitors Using Combination Therapy Comprising A PHY906 Extract, A Scutellaria baicalensis Georgi (S) Extract or A Compound From Such Extracts
Phuphanich et al. Phase I study of intravenous bromodeoxyuridine used concomitantly with radiation therapy in patients with primary malignant brain tumors
JPS5998015A (en) Immunoactivator
Cunningham et al. The pharmacokinetics of high dose cyclophosphamide and high dose etoposide
Nahata et al. Analgesic plasma concentrations of morphine in children with terminal malignancy receiving a continuous subcutaneous infusion of morphine sulfate to control severe pain
Novotny et al. Protein synthesis inhibitors of natural origin for CML therapy: semisynthetic homoharringtonine (Omacetaxine mepesuccinate)
Urtasun et al. Human pharmacokinetics and toxicity of high-dose metronidazole administered orally and intravenously
KR100310121B1 (en) Treatment of tumor diseases using thiazopurine and ribavirin
Brown et al. The optimum time for irradiation relative to tumour concentration of hypoxic cell sensitizers
Cunningham et al. Etoposide: a pharmacokinetic profile including an assessment of bioavailability
Ploin et al. Pharmacokinetically guided dosing for intravenous melphalan: a pilot study in patients with advanced ovarian adenocarcinoma
Ninane et al. High dose melphalan in children with advanced malignant disease: a pharmacokinetic study
CN115463127A (en) Application of brucea javanica picrol combined with 17-AAG as PD-L1 inhibitor